Combining the TGF-β1 blockade with immune checkpoint blockade therapy can effectively reverse the immunosuppressive state by increasing the number of Th1 and CD8+ T cells to achieve significant tumour regression and improve patient survival [75]. This evidence concerns the gene CD8A and neoplasm.